Phase I Study of PhOx430, a Glucosaminyltransferase V Inhibitor, in Adults with Advanced or Metastatic Solid Tumors Lacking Effective Treatment Options

The primary objective of this Phase I trial is to evaluate the safety and tolerability of **PhOx430**, a novel inhibitor of the enzyme glucosaminyltransferase V, in adult patients with advanced or metastatic solid malignancies. These patients have experienced radiologically documented progression on a previous line of treatment and lack effective treatment options. The clinical relevance of this study lies in its potential to offer a new therapeutic avenue for individuals with limited treatment alternatives, thereby addressing a significant unmet medical need in oncology.

The clinical trial involves **adult patients** with advanced or metastatic solid malignancies, characterized by radiologically documented progression on a previous line of treatment, for which effective treatment options do not exist. The study population includes both male and female participants, encompassing an **age range** of 18 years and older. The trial population was selected to include individuals who are part of a vulnerable population. However, the sponsor has not provided information regarding the total number of participants. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. Key inclusion or exclusion criteria have not been detailed by the sponsor.

The clinical trial is designed as a **Phase I** study to evaluate the safety and tolerability of a new drug, PhOx430, an inhibitor of the enzyme glucosaminyltransferase V, in adult patients with advanced or metastatic solid malignancies. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the investigators are aware of the treatment assignments, thereby minimizing bias. The trial is expected to span approximately six years, with an estimated recruitment start date of February 1, 2022, and an anticipated end date of February 1, 2028.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on specific criteria, including documented progression on a previous line of treatment and the absence of effective treatment options. Following successful screening, participants will be enrolled in the study and will attend regular follow-up visits to monitor safety, drug tolerability, and any adverse events. These visits will also include assessments of the drug's pharmacokinetics and pharmacodynamics. The end-of-study visit will occur at the conclusion of the treatment period, where final evaluations will be conducted to gather comprehensive data on the drug's effects.

The expected length of participant involvement in the trial will vary depending on individual response and tolerance to the treatment, but it is anticipated to last several months. Conditions that may lead to early termination from the study include significant adverse reactions, disease progression, or withdrawal of consent by the participant. The trial aims to provide critical data on the safety profile of PhOx430, contributing to the development of new therapeutic options for patients with limited treatment alternatives.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements cannot be provided.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date for the trial is February 1, 2022, with an anticipated completion date of February 1, 2028. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. The trial will likely employ standardized methods for measuring and collecting data, which may include validated scales, laboratory tests, or patient-reported outcomes, depending on the investigational product and the condition being studied. The analysis of efficacy data will be conducted in accordance with the trial's protocol, ensuring rigorous and scientifically sound conclusions. The absence of specific endpoints in the provided data suggests that the trial's primary focus may be on safety and tolerability, with efficacy assessments being exploratory in nature.